SuspendedNCT03513549
Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolarity type I
Observational studyAges 18+United States
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- RaleighSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 4, 2014
- Recruitment status
- Suspended
- Enrollment listed in the registry
- 10,000
- Sponsor
- Alexza Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Observational
- Intervention type
- Drug
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT03513549
- Official title
Show the full official title
A Postmarketing Observational Study to Evaluate the Safety of ADASUVE® (STACCATO® Loxapine for Inhalation) in Patients With Agitation Associated With Schizophrenia or Bipolar I Disorder
Recruitment & locations
SuspendedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Raleigh
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Alexza Pharmaceuticals, Inc.
Does this study involve medication?
Yes. The study involves medication, including Loxapine 10 MG.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as suspended.
